Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

被引:337
作者
Perren, A
Weng, LP
Boag, AH
Ziebold, U
Thakore, K
Dahia, PLM
Komminoth, P
Lees, JA
Mulligan, LM
Mutter, GL
Eng, C
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Med Res Facil 690C, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA
[3] Univ Zurich, Dept Pathol, CH-8006 Zurich, Switzerland
[4] Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada
[5] Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada
[6] MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA
[7] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[8] Harvard Univ, Sch Med, Boston, MA USA
[9] Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England
关键词
D O I
10.1016/S0002-9440(10)65227-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Germline mutations in PTEN, encoding a dual-specificity phosphatase on 10q23.3, cause Cowden syndrome (CS), which is characterized by a high risk of breast and thyroid cancers. Loss of heterozygosity of 10q22-24 markers and somatic PTEN mutations have been found to a greater or lesser extent in a variety of sporadic component and noncomponent cancers of CS, Among several series of sporadic breast carcinomas, the frequency of loss of flanking markers around PTEN is approximately 30 to 40%, and the somatic intragenic PTEN mutation frequency is <5%, In this study, we analyzed PTEN expression in 33 sporadic primary breast carcinoma samples using immunohistochemistry and correlated this to structural studies at the molecular level. Normal mammary tissue had a distinctive pattern of expression: myoepithelial cells uniformly showed strong PTEN expression. The PTEN protein level in mammary epithelial cells was variable. Ductal hyperplasia with and without atypia exhibited higher PTEN protein levels than normal mammary epithelial cells. Among the 33 carcinoma samples, 5 (15%) were immunohistochemically PTEN-negative; 6 (18%) had reduced staining, and the rest were PTEN-positive. In the PTEN-positive tumors as well as in normal epithelium, the protein was localized in the cytoplasm and in the nucleus (or nuclear membrane). Among the immunostain negative group, all had hemizygous PTEN deletion but no structural alteration of the remaining allele. Thus, in these cases, an epigenetic phenomenon such as hypermethylation, decreased protein synthesis or increased protein degradation may be involved. In the cases with reduced staining, 5 of 6 had hemizygous PTEN deletion and 1 did not have any structural abnormality. Finally, clinicopathological features were analyzed against PTEN protein expression. Three of the 5 PTEN immunostain-negative carcinomas were also both estrogen and progesterone receptor-negative, whereas only 5 of 22 of the PTEN-positive group were double receptor-negative. The significance of this last observation requires further study.
引用
收藏
页码:1253 / 1260
页数:8
相关论文
共 29 条
[21]  
Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.0.CO
[22]  
2-P
[23]  
STARINK TM, 1986, CLIN GENET, V29, P222
[24]   Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J].
Steck, PA ;
Pershouse, MA ;
Jasser, SA ;
Yung, WKA ;
Lin, H ;
Ligon, AH ;
Langford, LA ;
Baumgard, ML ;
Hattier, T ;
Davis, T ;
Frye, C ;
Hu, R ;
Swedlund, B ;
Teng, DHF ;
Tavtigian, SV .
NATURE GENETICS, 1997, 15 (04) :356-362
[25]  
Tashiro H, 1997, CANCER RES, V57, P3935
[26]   Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines [J].
Tsao, HS ;
Zhang, X ;
Benoit, E ;
Haluska, FG .
ONCOGENE, 1998, 16 (26) :3397-3402
[27]  
Wang SI, 1997, CANCER RES, V57, P4183
[28]   Antigen retrieval, signal amplification and intensification in immunohistochemistry [J].
Werner, M ;
vonWasielewski, R ;
Komminoth, P .
HISTOCHEMISTRY AND CELL BIOLOGY, 1996, 105 (04) :253-260
[29]   Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression [J].
Whang, YE ;
Wu, XY ;
Suzuki, H ;
Reiter, RE ;
Tran, C ;
Vessella, RL ;
Said, JW ;
Isaacs, WB ;
Sawyers, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5246-5250